4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Akeso, Inc. (9926) operates in the Biotechnology industry and is headquartered in Zhongshan, China with about 3,761 employees. Its market capitalization is roughly CNY 92 billion. In the fiscal year ended 2025-12-31, 9926 reported CNY 3.1B in revenue and (CNY 1.1B) in net income.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 3.1B | CNY 2.1B | CNY 4.5B | CNY 838M | — |
| Gross Profit | CNY 2.4B | CNY 1.8B | CNY 4.4B | CNY 744M | — |
| Operating Income (EBIT) | (CNY 848M) | (CNY 504M) | CNY 2.2B | (CNY 1.2B) | — |
| Net Income | (CNY 1.1B) | (CNY 514M) | CNY 2.0B | (CNY 1.2B) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 16.0B | CNY 12.8B | CNY 9.2B | CNY 5.5B | — |
| Total Liabilities | CNY 7.1B | CNY 6.0B | CNY 4.7B | CNY 2.9B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9926 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms